



(86) Date de dépôt PCT/PCT Filing Date: 2012/05/24
(87) Date publication PCT/PCT Publication Date: 2012/12/06
(45) Date de délivrance/Issue Date: 2021/01/12
(85) Entrée phase nationale/National Entry: 2013/11/26
(86) N° demande PCT/PCT Application No.: US 2012/039396
(87) N° publication PCT/PCT Publication No.: 2012/166533
(30) Priorité/Priority: 2011/05/27 (US61/490,652)

(51) Cl.Int./Int.Cl. *A61K 31/196* (2006.01),
A61K 31/198 (2006.01), *A61K 31/401* (2006.01),
A61K 45/06 (2006.01)


(72) Inventeurs/Inventors:
FOSTER, ALAN C., US;
LI, YONG-XIN, US;
STAUBLI, URSULA, US;
VISWANATH, VEENA, US;
LUHRS, LAUREN, US

(73) Propriétaire/Owner:
ALLERGAN, INC., US

(74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre : INHIBITEURS DU TRANSPORTEUR DE D-SERINE EN TANT QUE COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT DE TROUBLES DU SYSTEME VISUEL

(54) Title: D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS



(57) **Abstr  /Abstract:**

The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of visual system disorders and the enhancement of the visual function.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2012/166533 A1

(43) International Publication Date
6 December 2012 (06.12.2012)

WIPO | PCT

(51) International Patent Classification:

A61K 31/196 (2006.01) *A61K 31/401* (2006.01)
A61K 31/198 (2006.01) *A61K 45/06* (2006.01)

(21) International Application Number:

PCT/US2012/039396

(22) International Filing Date:

24 May 2012 (24.05.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/490,652 27 May 2011 (27.05.2011) US

(71) Applicant (for all designated States except US): **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, CA 92612 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FOSTER, Alan C.** [GB/US]; 5280 Vista Del Dios, San Diego, CA 92130 (US). **LI, Yong-Xin** [US/US]; 23885 Copenhagen St., Mission Viejo, CA 92691 (US). **STAUBLI, Ursula** [US/US]; 3019 Mountain View Dr., Laguna Beach, CA 92651 (US). **VISWANATH, Veena** [US/US]; 3 Pollena, Irvine, CA 92602 (US). **LUHRS, Lauren** [US/US]; 42 Santa Loretta, Rancho Santa Margarita, CA 92688 (US).

(74) Agents: **ENE, Doina** et al.; Allergan, Inc., 2525 Dupont Drive, Irvine, CA 92612 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS

Table 1: Inhibition of D-serine transport into rat brain synaptosomes and rat hippocampal astrocytes in culture by amino acid analogs.

Compound	IC ₅₀ in Astrocytes (μM)	IC ₅₀ in Synaptosomes (μM)
L-serine	57.9	9.6
D-serine	1581	9.4
L-glutamine	1641	943
L-asparagine	57.2	668
L-GPNA	3096	453
L-glutamate-γ-benzyl ester	3000	62
L-4-fluorophenylglycine	27.9	258
L-4-hydroxyphenylglycine	142.1	101
DL-2-fluorophenylglycine	1571	348
L-phenylglycine	89.4	217
L-proline	2271	>10,000
L-trans-4-hydroxyproline	38.9	>10,000
S-benzyl-L-cysteine	424	86
S-phenyl-L-cysteine	597	29.3

(57) Abstract: The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of visual system disorders and the enhancement of the visual function.

WO 2012/166533 A1



-
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- Published:**
- *with international search report (Art. 21(3))*

D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS

**By Inventors Alan C. Foster, Yong-Xin Li , Ursula Staubli,
Veena Viswanath and Lauren Luhrs**

5

Field of the Invention

The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical
10 compositions in methods for the treatment of visual system disorders and the enhancement of the visual function.

Background

Neuronal circuits in the central nervous system rely on the release of chemical neurotransmitters from specialized connections called synapses for communication.
15 The major excitatory neurotransmitter is the amino acid glutamate, and release of glutamate from a pre-synaptic terminal elicits a response through activation of several types of receptors. One of the sub-types of glutamate receptors, the N-methyl-D-aspartate (NMDA) receptor, plays a major role in neuronal communication and in the plasticity of synaptic responses that occurs under both physiological and
20 pathophysiological conditions.

NMDA receptors are ligand-gated cation channels comprised of a tetrameric assembly of NR1, NR2 and NR3 sub-units (Paoletti and Neyton, 2007). They are unique amongst neurotransmitter receptors in that they require occupation of two separate recognition sites for activation. An acidic amino acid site where glutamate
25 binds, is located on the NR2 sub-units, and a neutral amino acid (or co-agonist) site is located on the NR1 sub-unit. The endogenous co-agonist for this site was originally thought to be glycine, but more recent evidence indicated that D-serine is also an endogenous co-agonist. In fact, in higher brain regions D-serine may be the dominant co-agonist. Occupation of the co-agonist site is essential for glutamate (or
30 a glutamate analog) to activate the NMDA receptor, and in native assays the removal of glycine or D-serine by exogenously-applied degradative enzymes can reduce or abolish NMDA receptor-mediated responses. For example, in the rat

hippocampal slice, application of the D-serine metabolizing enzyme, D-amino acid oxidase (D-AAO), completely prevents the induction of long-term potentiation (LTP) a form of synaptic plasticity whose initiation is dependent on NMDA receptor activation (Yang et al., 2003). This suggests that the dominant co-agonist in this case is D-serine, since glycine is not a substrate for D-AAO.

The mechanisms that regulate extracellular D-serine, and therefore govern how NMDA receptors are activated, are not well understood. In keeping with other neurotransmitters and neuromodulators, it is likely that transporters on the cell surface are involved in regulating synaptic levels of D-serine. Amino acid transporters usually prefer L-amino acids, however D-serine has been shown to be a substrate for certain transporters. These include the heterodimeric transporter asc-1 (SLC3A2/SLC7A10) which has micromolar affinity for D-serine, ASCT2 (SLC1A5), ATB⁺ (SLC7A9) and PAT1-4 (SLC36A1-4). Based on the tissue and cellular localization, the primary candidates for transporters that regulate synaptic D-serine levels are asc-1 (neuronal) and ASCT2 (glial). The related transporter ASCT1 (SLC1A4) also has been localized to neurons and glia, however it has been reported that D-serine is not a substrate for ASCT1 (Shafqat et al., 1993). None of these transporters are selective for D-serine, and their substrates are typically small neutral amino acids such as serine, alanine, cysteine and threonine. They also are known to function as exchangers that can flux their substrates both into and out of cells. Consequently, it has been unclear if these transporters are responsible primarily for the net uptake or the net release of D-serine and other substrates. Considering that asc-1 has the highest known affinity for D-serine, it has been thought that this transporter is primarily responsible for removing D-serine from the extracellular space (Rutter et al., 2007). In support of this, the asc-1 knock-out mouse has a phenotype that includes increased excitability (Xie et al., 2005).

In the visual system, NMDA receptors are important mediators of glutamate-mediated neurotransmission and synaptic plasticity. This occurs at all levels of the visual axis, including neurons in the retina, in the central neurons that receive retinal ganglion cell input in the lateral geniculate nucleus and the superior colliculus, and in the visual cortex. Based on experiments using D-AAO, D-serine has been shown to be an endogenous co-agonist involved in NMDA-receptor-mediated synaptic responses in the retina (Stevens et al., 2003) NMDA receptors have also been

shown to mediate synaptic responses in the lateral geniculate (Harveit & Heggelund, 1990; Scharfman et al., 1990) and the visual cortex (ie the primary pathways that transduce visual information). In the visual cortex, NMDA receptors mediate the phenomenon of long-term potentiation (LTP), an important form of synaptic plasticity.

5 NMDA receptor-dependent LTP occurs in many brain regions and is viewed as a mechanism of synaptic strengthening that is fundamental to the establishment and maintenance of appropriate synaptic connections. In the hippocampus, for example, LTP has been studied as a synaptic surrogate of learning and memory. In visual cortex neurons, LTP mediates stimulus-specific response potentiation, a form of
10 experience-dependent plasticity that contributes to visual function (Cooke and Bear, 2010).

In retinal diseases such as glaucoma and macular degeneration, loss of the vision arises from degeneration or malfunction of retinal cells. Consequently, the normal neuronal transmission along the visual pathway is disrupted in the affected
15 parts of the visual field. One strategy to remedy this loss of function would be to enhance the visual neurotransmission that remains unaffected by disease to compensate for the region of impairment. In addition, enhancing the plasticity of neuronal connections that occurs in the adult visual system could lead to the establishment of new neuronal connections that replace the lost function and
20 improve visual performance.

Enhancing NMDA receptor activity by increasing the extracellular levels of D-serine would boost visual performance and compensate for the loss of vision resulting from retinal disease. As a result, we have discovered compounds that inhibit the transport of D-serine and enhance NMDA receptor-mediated synaptic
25 responses. We identified the D-serine transporters that are important for regulating NMDA receptor-mediated LTP in the visual cortex, and we demonstrated that D-serine transport inhibitors improve visual function in animal models of retinal disease.

Summary of the Invention

The present invention relates to the use of pharmaceutical compositions comprising
30 D-serine transporter inhibitor compound(s) in methods for the treatment of visual system disorders.

Visual system disorders which may be treated with the D-serine transport inhibitors include macular edema, dry and wet macular degeneration, choroidal

neovascularization, diabetic retinopathy, acute macular neuroretinopathy, central serous chorioretinopathy, cystoid macular edema, and diabetic macular edema, uveitis, retinitis, choroiditis, acute multifocal placoid pigment epitheliopathy, Behcet's disease, birdshot retinochoroidopathy, syphilis, lyme, tuberculosis, toxoplasmosis, intermediate uveitis (pars planitis), multifocal choroiditis, multiple evanescent white dot syndrome (mewds), ocular sarcoidosis, posterior scleritis, serpiginous choroiditis, subretinal fibrosis and uveitis syndrome, Vogt-Koyanagi-and Harada syndrome; retinal arterial occlusive disease, anterior uveitis, retinal vein occlusion, central retinal vein occlusion, disseminated intravascular coagulopathy, branch retinal vein occlusion, hypertensive fundus changes, ocular ischemic syndrome, retinal arterial microaneurysms, Coat's disease, parafoveal telangiectasis, hemiretinal vein occlusion, papillophlebitis, central retinal artery occlusion, branch retinal artery occlusion, carotid artery disease (CAD), frosted branch angiitis, sickle cell retinopathy, angioid streaks, familial exudative vitreoretinopathy, and Eales disease; traumatic/surgical conditions such as sympathetic ophthalmia, uveitic retinal disease, retinal detachment, trauma, photocoagulation, hypoperfusion during surgery, radiation retinopathy, and bone marrow transplant retinopathy; proliferative vitreal retinopathy and epiretinal membranes, and proliferative diabetic retinopathy; infectious disorders such as ocular histoplasmosis, ocular toxocariasis, presumed ocular histoplasmosis syndrome (POHS), endophthalmitis, toxoplasmosis, retinal diseases associated with HIV infection, choroidal disease associate with HIV infection, uveitic disease associate with HIV infection, viral retinitis, acute retinal necrosis, progressive outer retinal necrosis, fungal retinal diseases, ocular syphilis, ocular tuberculosis, diffuse unilateral subacute neuroretinitis, and myiasis; genetic disorders such as retinitis pigmentosa, systemic disorders with associated retinal dystrophies, congenital stationary night blindness, cone dystrophies, Stargardt's disease and fundus flavimaculatus, Best's disease, pattern dystrophy of the retinal pigmented epithelium, X-linked retinoschisis, Sorsby's fundus dystrophy, benign concentric maculopathy, Bietti's crystalline dystrophy, and pseudoxanthoma elasticum; retinal tears/holes such as retinal detachment, macular hole, and giant retinal tear; tumors such as retinal disease associated with tumors, congenital hypertrophy of the retinal pigmented epithelium, posterior uveal melanoma, choroidal hemangioma, choroidal osteoma, choroidal metastasis, combined hamartoma of the

retina and retinal pigmented epithelium, retinoblastoma, vasoproliferative tumors of the ocular fundus, retinal astrocytoma, and intraocular lymphoid tumors; punctate inner choroidopathy, acute posterior multifocal placoid pigment epitheliopathy, myopic retinal degeneration, acute retinal pigment epitheliitis, retinitis pigmentosa, proliferative vitreal retinopathy (PVR), age-related macular degeneration (ARMD), diabetic retinopathy, diabetic macular edema, retinal detachment, retinal tear, uveitis, cytomegalovirus retinitis, glaucoma, amblyopia, stroke-induced blindness, visual dysfunction in Parkinson's disease, Alzheimer's disease and multiple sclerosis, seizure-induced cortical blindness, induced visual dysfunction, and epileptic blindness.

Description of the Drawings and Tables

Table 1 shows the ability of selected amino acids to inhibit D-serine transport into neurons (rat brain synaptosomes) and glia (rat hippocampal astrocytes). Values are the concentration of amino acid required to inhibit 50% of [³H]D-serine transport (IC₅₀) in μM, and are the means of at least two determinations. L-GPNA: L-γ-nitrophenyl glutamyl anilide.

Table 1: Inhibition of D-serine transport into rat brain synaptosomes and rat hippocampal astrocytes in culture by amino acid analogs.

Compound	IC ₅₀ in Astrocytes (μM)	IC ₅₀ in Synaptosomes (μM)
L-serine	57.9	9.6
D-serine	1581	9.4
L-glutamine	1641	943
L-asparagine	57.2	668
L-GPNA	3096	453
L-glutamate-γ-benzyl ester	3000	62
L-4-fluorophenylglycine	27.9	258
L-4-hydroxyphenylglycine	142.1	101
DL-2-fluorophenylglycine	1571	348
L-phenylglycine	89.4	217
L-proline	2271	>10,000
L-trans-4-hydroxyproline	38.9	>10,000
S-benzyl-L-cysteine	424	86
S-phenyl-L-cysteine	597	29.3

Figure 1A represents a graph displaying the electrophysiological recording from rat hippocampal slices and showing that L-4OHPG (L-4-hydroxyphenylglycine)

potentiates NMDA receptor-mediated excitatory postsynaptic currents (EPSC_{NMDA}). The representative experiment shows that the potentiation effect of L-4OHPG (1000 μ M) lasted for one hour and then returned to baseline in control buffer. 1000 is the concentration of L-4OHPG in μ M and 22% refers to the percentage increase in the amplitude of EPSC_{NMDA}. Dots represent the amplitudes of EPSC_{NMDA}. Filled triangles represent control; open circles represent 1 μ M 7-CKY and filled circles represent 1000 μ M L-4OHPG. 7-CKY is a competitive inhibitor at the D-serine site of the NMDA receptor, which inhibits the NMDA receptor-mediated EPSCs and increases the sensitivity of EPSC_{NMDA} to D-serine.

Figure 1B represents a graph featuring summary data showing the dose-dependent effects of L-4OHPG on EPSC_{NMDA}.

Figure 2A represents a graph showing that L-4OHPG dose-dependently facilitates long-term potentiation (LTP) in the primary visual cortex of rats.

Figure 2B represents a graph that features the results of exposing visual cortex slices to D-amino acid oxidase (DAAO), an enzyme that selectively degrades extracellular D-serine. The data suggest that L-4OHPG's enhancement of LTP in the visual cortex slice of rats is dependent on extracellular D-serine.

Figure 3A represents a graph that shows the correlation between the ability of compounds to inhibit neuronal D-serine transport and the threshold concentration required to enhance LTP in the visual cortex slice. The r^2 value (correlation coefficient) and p value (probability) indicates that no significant correlation exists.

Figure 3B represents a graph that shows the correlation between the ability of compounds to inhibit astrocyte D-serine transport and the threshold concentration required to enhance LTP in the visual cortex slice. The r^2 value (correlation coefficient) and p value (probability) indicates that a highly significant correlation exists.

Figure 4 represents a graph that shows the 2-component inhibition of D-serine transport into astrocytes by L-glutamine and L-trans-4-hydroxyproline (L-t-4OHPro) and IC₅₀ values for the individual components. Two-component inhibition curves were fitted using an algorithm available in GraphPad Prism 4. "Component 1" is the high affinity component and "Component 2" is the low affinity component. "Fraction" refers to the proportion that each component contributes to the total inhibition. Results are provided in Table 2.

Table 2

Compound	Component 1 IC ₅₀ μ M	Component 2 IC ₅₀ μ M	Component 1 Fraction (%)
L-glutamine	26.9	2737	36.7
L-t-4OHPro	17.2	2989	61.1

Figure 5 shows results of inhibition of [³H]L-serine transport into parental HEK cells and HEK cells expressing ASCT1 and ASCT2 by L-glutamine and L-t-4OHPro.

- 5 SLC1A4 is the gene name for ASCT1 and SLC1A5 is the gene name for ASCT2. Results are provided in Table 3.

Table 3

IC ₅₀ μ M	ASCT1 (SLC1A4)	ASCT2 (SLC1A5)
L-glutamine	3373	541
L-t-4OHPro	188	3475

- Figure 6A** represents a graph that shows transport of [³H]D-serine into HEK cells expressing ASCT1 or ASCT2. Transport was measured in the presence (control) and in the absence (zero Na) of extracellular sodium.

Figure 6B represents a graph that shows the inhibition of [³H]L-serine transport into astrocytes and HEK cells expressing ASCT1 and ASCT2 by D-serine. Results are provided in Table 4.

15

Table 4

D-serine IC ₅₀ μ M		
Astrocytes	ASCT1(SLC1A4)	ASCT2(SLC1A5)
2592	3937	4913

Table 5 shows IC₅₀ values for the inhibition of [³H]L-serine transport into astrocytes and HEK cells expressing recombinant human ASCT1 or ASCT2. Values

are IC₅₀'s in μ M from 6-12 point inhibition curves, with an n of at least 2. For L-trans-4-hydroxyproline (L-t-4OHPro) and L-GPNA, two components of inhibition were present in the astrocyte assay, and *values are presented for the high and low affinity components. For comparison, threshold concentrations for the enhancement of LTP in rat visual cortex slices are shown.

Table 5

Compound	IC₅₀ Astrocytes (μM)	IC₅₀ ASCT1 (μM)	IC₅₀ ASCT2 (μM)	LTP Threshold (μM)
L-serine	94	292	822	NA
D-serine	2592	3937	4913	3
L-glutamine	41* 4713*	3373	541	NA
L-asparagine	108	656	674	3
L-GPNA	57* 4135*	>10,000	1133	100
L-4-fluorophenylglycine	83.3	377	437	0.3
L-4-hydroxyphenylglycine	283	1322	1728	10
DL-2-fluorophenylglycine	1572	>3000	>3000	>300
L-phenylglycine	228	1217	945	10
L-proline	1780	2139	>10,000	NA
L-trans-4-hydroxyproline	16* 3047*	188	3475	3
L-cyclopropylglycine	180	948	428	1

* values for high and low affinity components

NA = not applicable.

Figure 7 represents the correlation of the IC₅₀ values from the transport assays (see Table 5 and accompanying explanation) with the LTP threshold data (see Figure 2A and accompanying explanation). Graph A shows the correlation between the IC₅₀ values for the ASCT1 transporter (also known as SLC1A4) and the LTP threshold data; graph B shows the correlation between the IC₅₀ values for the ASCT2 transporter (also known as SLC1A5) and the LTP threshold data; graph C shows the correlation between the product of both ASCT1's and ASCT2's IC₅₀ values and the LTP threshold data in order to take into account how contributions from both transporters might be important to produce the LTP enhancement (this plot gives the best correlation and suggests that inhibition of both transporters, leads to optimal LTP enhancement).

Figure 8 shows that L-4OHPG enhances visual function in normal rats as assessed by sweep VEP. Saline was used as a control. Half of the rats were

injected with 30 mg/kg L-4OHPG and the other half with saline in the first test; cross-over exposure took place one week later; the spatial frequencies were swept from 0.03 cycles per degree (cpd) to 1.6 cpd. Graphs A and B show visual acuity (VA) values for each rat measured before and 30 min after saline (A) or L-4OHPG (B) injection, and the average VA values from all rats are shown in D. The changes in VA measures are shown in C and E.

Figure 9 shows that L-4-fluorophenylglycine (L-FPG) enhances visual function in normal rats as assessed by sweep VEP. Saline was used as a control. Half of the rats were injected with 10 mg/kg L-FPG and the other half with saline in the first test; cross-over exposure took place one week later; the spatial frequencies were swept from 0.03 cpd to 1.6 cpd. VA before and 40 min after L-FPG (graph A) or saline (graph B) injection are compared in individual rats and the average VA values are shown in D. The changes in VA measures are shown in C and E.

Figure 10 shows the visual enhancement effect of L-4OHPG in the ONC rat. Saline was used as a control. Half of the rats were injected with 30 mg/kg L-4OHPG and the other half with saline in the first test; cross-over exposure took place one week later; the spatial frequencies were fixed at 0.2 cpd. **Graph A** and **Graph B** show data collected 30 min before and after L-4OHPG or saline injection. The changes in the power of signals are shown in C and D.

Figure 11 shows that L-4OHPG enhances visual function in normal rabbits as assessed by sweep VEP. Saline was used as a control. Half of the rats were injected with 30 mg/kg L-4OHPG and the other half with saline in the first test; cross-over exposure took place one week later. the spatial frequencies were swept from 0.03 cycles per degree (cpd) to 1.6 cpd.

Figure 12 shows that 4-FPG improved the contrast sensitivity impaired in rats fifty-three weeks after blue-light treatment. Saline was used as a control. Half of the rats were injected with 10 mg/kg 4-FPG and the other half with saline in the first test; cross-over exposure took place one week later; the spatial frequencies were fixed at 0.575 cpd.

Detailed Description of the Invention

In one aspect the invention relates to a method for the treatment of visual system disorders caused by a deficit in N-methyl –D-aspartate receptor function, the method comprising administering to a subject in need thereof an ophthalmically acceptable pharmaceutical composition containing a therapeutically effective amount of one or more D-serine transporter inhibitor compounds.

In another aspect the invention relates to a method for the treatment of visual system disorders, the method comprising administering to a subject in need thereof an ophthalmically acceptable pharmaceutical composition containing a therapeutically effective amount of one or more D-serine transporter inhibitor compounds selected from the Glycine/Alanine family, the Glutamine/Asparagine family, the Tryptophan Family, the Phenylglycine family, the Phenylalanine family, the Cysteine family, the Serine/Threonine family, the Cyclic Amino Acid family and the Proline family.

In another aspect the invention relates to a method for the treatment of visual system disorders, the method comprising administering to a subject in need thereof an ophthalmically acceptable pharmaceutical composition containing a therapeutically effective amount of one or more D-serine transporter inhibitor compounds selected from L-gamma-glutamyl-4-nitroanilide, L-4-hydroxyphenylglycine, L-4-fluorophenylglycine, L-phenylglycine, trans-4-hydroxy-L-proline and R-gamma-2,4-dichlorobenzyl-L-proline.

In another aspect the invention relates to a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of at least one D-serine transporter inhibitor compound and a pharmaceutically acceptable adjuvant, diluents or carrier.

In another aspect the invention relates to a method for the treatment of visual system disorders caused by a deficit in N-methyl –D-aspartate receptor function, the method comprising administering to a subject in need thereof an ophthalmically acceptable pharmaceutical composition containing a therapeutically effective amount of at least one or more ASCT1 inhibitor compounds and/or at least one or more ASCT1 inhibitor compounds.

In another aspect the invention relates to a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of at least one or

more ASCT1 inhibitor and/or at least one or more ASCT2 inhibitor and a pharmaceutically acceptable adjuvant, diluents or carrier.

In another aspect the invention relates to a method for the enhancement of visual function, the method comprising administering to a subject in need thereof an
5 ophthalmically acceptable pharmaceutical composition containing a therapeutically effective amount of one or more D-serine transporter inhibitor compounds.

In another aspect the invention relates to a method for the enhancement of visual function, the method comprising administering to a subject in need thereof an ophthalmically acceptable pharmaceutical composition containing a therapeutically
10 effective amount of one or more D-serine transporter inhibitor compounds selected from the group consisting of the Glycine/Alanine family, the Glutamine/Asparagine family, the Tryptophan Family, the Phenylglycine family, the Phenylalanine family, the Cysteine family, the Serine/Threonine family, the Cyclic Amino Acid family and the Proline family.

In another aspect the invention relates to a method for the enhancement of visual function, the method comprising administering to a subject in need thereof an ophthalmically acceptable pharmaceutical composition containing a therapeutically effective amount of one or more D-serine transporter inhibitor compounds selected from the group consisting of L-gamma-glutamyl-4-nitroanilide, L-4-
20 hydroxyphenylglycine, L-4-fluorophenylglycine, L-phenylglycine, trans-4-hydroxy-L-proline and R-gamma-2,4-dichlorobenzyl-L-proline.

In another aspect the invention relates to a method for the enhancement of visual function, the method comprising administering to a subject in need thereof an ophthalmically acceptable pharmaceutical composition containing a therapeutically
25 effective amount of at least one or more ASCT1 inhibitor and/or at least one or more ASCT2 inhibitor compounds.

In another aspect the invention relates to a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of L-gamma-glutamyl-4-nitroanilide and a pharmaceutically acceptable adjuvant, diluents or
30 carrier.

In another aspect the invention relates to a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of L-4-

hydroxyphenylglycine and a pharmaceutically acceptable adjuvant, diluents or carrier.

In another aspect the invention relates to a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of L-4-fluorophenylglycine and a pharmaceutically acceptable adjuvant, diluents or carrier.

In another aspect the invention relates to a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of L-phenylglycine and a pharmaceutically acceptable adjuvant, diluents or carrier.

In another aspect the invention relates to a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of trans-4-hydroxy-L-proline and a pharmaceutically acceptable adjuvant, diluents or carrier.

In another aspect the invention relates to a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of R-gamma-2,4-dichlorobenzyl-L-proline and a pharmaceutically acceptable adjuvant, diluents or carrier.

In another aspect, the present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of visual system disorders.

In another aspect, the present invention relates to a method for the enhancement of visual function comprising administration of one or more D-serine transporter inhibitors by different administration routes. D-serine transporter inhibitors were identified as compounds that inhibit transport mechanisms in neurons and astrocytes, in D-serine transport assays *in vitro*.

Enhancement of visual function means administering one or more of the D-serine transport inhibitor compounds to improve the visual function, to alleviate its severity, to prevent the onset of a disorder, and to prevent its reoccurrence. Visual function includes visual acuity, visual field, night vision, color vision, dark/light adaptation, contrast sensitivity, binocular vision, motion detection, etc.

In another aspect the present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one D-serine transporter inhibitor compound, said compound being present alone or in combination with one or more pharmaceutically acceptable excipients.

In another aspect the present invention relates to a method for the treatment of visual system disorders caused by a deficit in N-methyl –D-aspartate receptor function, the method comprising administering to a subject in need thereof an ophthalmically acceptable pharmaceutical composition containing a therapeutically effective amount of one or more D-serine transporter inhibitor compounds.

In another aspect the present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one compound selected from the group consisting of ASCT1 inhibitor, ASCT2 inhibitor, and combinations thereof, said compound being present alone or in combination with one or more pharmaceutically acceptable excipients.

In another aspect the present invention relates to a method for the treatment of visual system disorders caused by a deficit in N-methyl –D-aspartate receptor function, the method comprising administering to a subject in need thereof an ophthalmically acceptable pharmaceutical composition containing a therapeutically effective amount of one or more compounds selected from the group consisting of ASCT1 inhibitor, ASCT2 inhibitor, and combinations thereof.

In another aspect the present invention relates to a method for the enhancement of visual function, the method comprising administering to a subject in need thereof an ophthalmically acceptable pharmaceutical composition containing a therapeutically effective amount of one or more compounds selected from the group consisting of ASCT1 inhibitor, ASCT2 inhibitor, and combinations thereof.

In another aspect the present invention relates to a method for the treatment of visual system disorders caused by a deficit in N-methyl –D-aspartate receptor

function, the method comprising administering to a subject in need thereof an ophthalmically acceptable pharmaceutical composition containing a therapeutically effective amount of L-gamma-glutamyl-4-nitroanilide L-4-hydroxyphenylglycine, L-4-fluorophenylglycine, L-phenylglycine, trans-4-hydroxy-L-proline, R-gamma-2,4-dichlorobenzyl-L-proline.

The actual amount of the compound to be administered in any given case will be determined by a physician taking into account the relevant circumstances, such as the severity of the condition, the age and weight of the patient, the patient's general physical condition, the cause of the condition, and the route of administration.

The patient will be administered the compound orally in any acceptable form, such as a tablet, liquid, capsule, powder and the like, or other routes may be desirable or necessary, particularly if the patient suffers from nausea. Such other routes may include, without exception, transdermal, parenteral, subcutaneous, intranasal, via an implant stent, intrathecal, intravitreal, topical to the eye, back of the eye, front of the eye, intramuscular, intravenous, and intrarectal modes of delivery. Additionally, the formulations may be designed to delay release of the active compound over a given period of time, or to carefully control the amount of drug released at a given time during the course of therapy.

In another embodiment of the invention, there are provided pharmaceutical compositions including at least one compound of the invention in a pharmaceutically acceptable carrier thereof. The phrase "pharmaceutically acceptable" means the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Pharmaceutical compositions of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a patch, a micelle, a liposome, and the like, wherein the resulting composition contains one or more compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications. Invention compounds may be combined, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch

paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used.

- 5 Invention compounds are included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or disease condition.

Pharmaceutical compositions containing invention compounds may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or
10 syrups or elixirs. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of a sweetening agent such as sucrose, lactose, or saccharin, flavoring agents such as peppermint, oil of wintergreen or cherry, coloring agents and
15 preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets containing invention compounds in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods. The excipients used may be, for example, (1) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating
20 and disintegrating agents such as corn starch, potato starch or alginic acid; (3) binding agents such as gum tragacanth, corn starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a
25 longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.

In some cases, formulations for oral use may be in the form of hard gelatin capsules wherein the invention compounds are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the
30 form of soft gelatin capsules wherein the invention compounds are mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

The pharmaceutical compositions may be in the form of a sterile injectable suspension. This suspension may be formulated according to known methods using

suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides, fatty acids (including oleic acid), naturally occurring vegetable oils like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or synthetic fatty vehicles like ethyl oleate or the like. Buffers, preservatives, antioxidants, and the like can be incorporated as required.

Invention compounds may also be administered in the form of suppositories for rectal administration of the drug. These compositions may be prepared by mixing the invention compounds with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters of polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.

Since individual subjects may present a wide variation in severity of symptoms and each drug has its unique therapeutic characteristics, the precise mode of administration and dosage employed for each subject is left to the discretion of the practitioner.

An ophthalmically acceptable pharmaceutical composition is one that can be administered topically to the eye of a subject in need thereof. Comfort to the subject being administered the composition should be maximized, but other considerations, such as drug stability, may necessitate a pharmaceutical composition that provides less than optimal comfort. In such a case, the composition should be formulated such that it is tolerable to a subject being administered the composition topically.

The claimed pharmaceutical composition can be administered topically in the form of solutions or suspensions, ointments, gels, creams, etc. A "pharmaceutically acceptable excipient" is one that is compatible with the active ingredient of the composition and not harmful to the subject being administered the pharmaceutical composition. Solutions for ophthalmic application are often prepared using physiological saline as a major vehicle. Other vehicles include polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose, and purified water. Examples of useful excipients also

include preservatives, buffers, other pH adjustors, tonicity adjustors, surfactants, antioxidants, and chelating agents.

Useful preservatives include benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate. Examples of buffers
5 include phosphate, borate, sulfate, acetate, and citrate buffers. Acids or bases may be used to adjust the pH of the compositions as needed. Examples of tonicity agents include glycerin, mannitol, sodium chloride and potassium chloride. Useful surfactants include, for example, Tween 80. Examples of ophthalmically acceptable antioxidants include sodium metabisulfite, sodium thiosulfate, acetylcysteine,
10 butylated hydroxyanisole and butylated hydroxytoluene. A useful chelating agent is edentate disodium.

Mixtures of two or more of any suitable excipients may be used.

Aside from topical application to treat diseases affecting the eye including glaucoma, pharmaceutical compositions containing at least one compound of
15 formula (I) can also be administered periorcularly, intraocularly, or by other effective means available in the art.

Persons skilled in the art would readily understand that a drug containing one or more of the compounds disclosed herein can be conformed as a powder, pill, tablet or the like, or as a solution, emulsion, suspension, aerosol, syrup or elixir suitable for
20 oral or parenteral administration or inhalation. For solid dosage forms or medicaments, non-toxic solid excipients for admixture with compounds disclosed herein include, but are not limited to, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, polyalkylene glycols, talcum, cellulose, glucose, sucrose, and magnesium carbonate. The solid dosage forms
25 may be coated by a material such as glyceryl monostearate or glyceryl distearate, which is utilized in known techniques to delay disintegration and absorption in the gastrointestinal tract for the purpose of providing a sustained action over a longer period. Solid dosage forms may also be coated by the techniques described in U.S. patents no. 4,256,108, 4,166,452 and 4,265,874 to form osmotic therapeutic tablets
30 for control release.

Pharmaceutically administrable liquid dosage forms can, for example, comprise a solution or suspension of at least one of the compounds disclosed herein and optional pharmaceutical adjutants in a carrier, such as water, saline, aqueous

dextrose, glycerol, ethanol and the like. The liquid dosage forms may also contain nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like. Examples of such auxiliary agents include sodium acetate, sorbitan monolaurate, triethanolamine, sodium acetate, triethanolamine oleate, etc.

5 Methods for preparing such dosage forms are well-known to persons skilled in the art (see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 16th Edition, 1980).

Parenteral administration is generally characterized by subcutaneous, intramuscular, or intravenous injection. Injectables can be prepared as liquid
10 solutions or suspensions, solid forms that can be reconstituted into solutions or suspensions prior to injection, or as emulsions. Suitable excipients include water, saline dextrose, glycerol, ethanol and the like. Such injectable pharmaceutical compositions may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffers and the like.

15 Examples mentioned herein are not intended to limit the scope of the invention in any way.

Using D-serine transport assays *in vitro*, we have identified compounds that inhibit transport mechanisms in neurons and astrocytes. In Table 1, the activities of amino acid analogs to inhibit D-serine transport are shown. Under the assay conditions
20 used, the sodium-independent transport of D-serine by rodent forebrain synaptosomes is mediated by asc-1 (Rutter et al., 2007), and the sodium-dependent transport of D-serine into astrocytes in culture is mediated by an ASCT transporter, ASCT2 according to the literature (Ribeiro et al., 2002).

The data presented herein shows that transport of D-serine into neurons and into
25 astrocytes can be pharmacologically distinguished. Analogs of glutamine, phenylglycine, asparagine, cysteine and proline were able to select between the two transport systems.

To determine the effects of transport inhibition on NMDA receptor function, compounds were tested for their ability to affect NMDA receptor-mediated synaptic
30 responses in brain slice preparations. L-4-hydroxyphenylglycine (L-4OHPG) potentiated NMDA receptor mediated excitatory post-synaptic currents (EPSC's) in the CA1 region of the hippocampus (Figure 1A and Figure 1B). In the visual cortex slice, LTP evoked by theta burst stimulation was enhanced by L-4OHPG. L-4OHPG

enhanced LTP in a concentration-dependent manner, and its effects were completely prevented by inclusion of D-AAO in the perfusion medium, indicating that its ability to enhance synaptic plasticity was dependent on extracellular D-serine (Figure 2B). Importantly, none of the compounds identified as D-serine transport inhibitors had significant direct effects on the NMDA receptor (or other glutamate receptor sub-types) as assessed in cultured hippocampal neurons.

In an attempt to understand the relative contributions of the neuronal and astrocyte D-serine transporters to the observed ability of compounds to enhance NMDA receptor-mediated responses, correlations were made between the effects of compounds in the transport assays and in the visual cortex slice LTP assay. A poor correlation was found between the effects in the neuronal transport assay and LTP (Figure 3A, $r^2 = 0.047$) however an excellent correlation existed between the effects in the astrocyte transport assay and LTP (Figure 3B, $r^2 = 0.902$). This indicated that the transporters present in astrocytes are those that regulate extracellular D-serine to influence NMDA receptor-mediated synaptic events.

The sodium-dependent D-serine transporter in astrocytes has been reported to be ASCT2 (Ribeiro et al., 2002). In the D-serine transport experiments in astrocytes, we noticed that some compounds produced inhibition curves that exhibited two components, suggesting that more than one transport component was present. In particular, two compounds defined the two components. L-glutamine showed higher affinity for a component that represented approximately 40% of the D-serine transport, and L-trans-4-hydroxyproline (L-t-4OHPro) showed higher affinity for a component that represented approximately 60% of the D-serine transport (Figure 4). Competition studies with each of these compounds in the presence of the other indicated that L-glutamine had high affinity for the component with low affinity for L-t-4OHPro and vice versa. PCR studies have indicated that both ASCT1 and ASCT2 transporter sub-types are present in astrocytes (Yamamoto et al., 2004). However, functional expression of ASCT1 and ASCT2 in heterologous systems has indicated that, unlike ASCT2, ASCT1 does not transport D-serine (Shafqat et al., 1993). L-glutamine is reported to have high affinity for ASCT2 (range of 23-70 μ M; Utsunomiya-Tate et al., 1996; Broer et al., 1999; Torres-Zamorano et al., 1998), and one report indicates that L-t-4OHPro has high affinity for ASCT1 (Pinilla-Tenas et al., 2003). We confirmed the selectivity of L-glutamine and L-t-4OHPro for the ASCT

sub-types by examining transport in HEK cells heterologously expressing human ASCT1 and ASCT2. For these experiments, [³H]L-serine was used since it is a high affinity substrate for both sub-types. As shown in Figure 5, L-glutamine inhibited transport and showed selectivity towards ASCT2, whereas L-t-4OHPro showed
5 selectivity towards ASCT1. Consequently, the two components of transport observed in astrocytes most likely represent ASCT1 (L-t-4OHPro-preferring) and ASCT2 (L-glutamine-preferring). If this is the case, however, it would suggest that ASCT1 does indeed transport D-serine, contrary to the literature report (Pinilla-Tenas et al., 2003). To investigate this, we examined transport into ASCT1-expressing HEK cells. As
10 shown in Figure 6A, [³H]D-serine was transported into ASCT1-expressing HEK cells in a sodium-dependent manner and to a similar degree to the transport observed in ASCT2-expressing HEK cells. In addition, [³H]L-serine transport was completely inhibited by D-serine in astrocytes and ASCT1 and ASCT2-expressing HEK cell lines (Figure 6B) as would be expected if D-serine interacts with both transporter sub-
15 types. Consequently, we have discovered that D-serine is indeed a substrate for ASCT1 with an affinity similar to that for ASCT2.

Given this evidence that transport into astrocytes is mediated by both ASCT1 and ASCT2, which of these transporter sub-types is primarily responsible for the inhibition of D-serine transport that leads to the enhancement of LTP observed? To
20 address this, we examined the ability of the inhibitors identified in the astrocyte transport assay and that enhance LTP to inhibit transport in the HEK cells expressing each ASCT sub-type. As shown by the experimental results herein, L-glutamine and the L-glutamine analog L-gamma-glutamyl-4-nitroanilide (L-GPNA) were selective for ASCT2. L-trans-4OHPro was selective for ASCT1. The
25 phenylglycine analogs, isomers of serine, asparagine and cyclopropylglycine showed equal ability to inhibit both sub-types. Correlations between the IC₅₀ values for transport inhibition at the sub-types and the threshold concentrations to enhance LTP revealed no significant correlation with ASCT1 (Figure 7a) but a significant correlation with ASCT2 (Figure 7b), however the best correlation was obtained when
30 the contribution of both sub-types was taken into account (product of the IC₅₀'s for both ASCT1 and ASCT2; Figure 7c). This suggests that both sub-types are important for the enhancement of LTP and that dual sub-type inhibitors are the most effective compounds.

Examples of D-serine Transporter Inhibitors

It has been found that certain amino acids of the Glycine/Alanine family, the Glutamine/Asparagine family, the Tryptophan Family, the Phenylglycine family, the Phenylalanine family, the Cysteine family, the Serine/Threonine family, the
5 Cyclic Amino Acid family and the Proline family are examples of D-serine transporter inhibitors.

The following are non-limiting examples of D-serine transporter inhibitors which are useful in the practice of the present invention. The amino acids that were tested for D-serine transport inhibition properties were obtained from Sigma-Aldrich,
10 Tocris Bioscience, Tyger Chemical Scientific, Bachem, ChemBridge Corporation, Matrix Scientific, PI Chemicals Inc., Toronto Research Chemicals and Maybridge Chemicals.

Table 6 Active Compounds by Amino Acid Family

Criterion for activity: $\geq 25\%$ inhibition of [^3H]D-serine transport into rat hippocampal
15 astrocytes at 1mM

Table 6

Glycine/Alanine Family	
<i>Compound</i>	<i>Isomer</i>
glycine	
alanine	L
2-aminobutyrate	L
2-allylglycine	DL
valine	L
3-(methylamino)alanine	L
1-aminocyclopropane-1-carboxylic acid	
1-aminocyclobutane-1-carboxylic acid	
1-aminocyclopentane-1-carboxylic acid	
α -cyclopropylglycine	L
phenylglycine	L
tetrazol-5yl glycine	DL
3-thienylglycine	L

aminocyclohexyl acetic acid	L
aminofuran-2-yl acetic acid	L
amino-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-acetic acid	DL
aminonaphthalen-1-yl acetic acid	L
aminobicyclo[2.2.1]hept-5-en-2-yl acetic acid	DL
dihydrophenylglycine	D
1-adamantyl(amino)acetic acid	
2-aminoadamantine-2-carboxylic acid	
3-benzoylalanine	DL
3-(2-thienyl)-alanine	L
3-cyclopentyl-alanine	L
3(2-naphthyl)-alanine	L
3-benzothienylalanine	L
azidohomoalanine	L
homopropargylglycine	L
valine	L
norvaline	L
alanine	D

Glutamine/Asparagine Family	
<i>Compound</i>	<i>Isomer</i>
glutamine	L
glutamate- γ -hydroxamate	L
glutamate- γ -4-nitroanilide	L
glutamate- γ -anilide	DL
glutamate- γ -(α -naphthylamide)	L
glutamate- γ -(β -naphthylamide)	L
glutamate- γ -(β -naphthylamide)	L
glutamate- γ -methylester	L
☐ glutamate- γ -ethylester	L
asparagine	L

asparagine	D
N-4-phenylasparagine	DL
kynurenine	L
kynurenine	D
3-hydroxy kynurenine	DL
2-amino-succinic acid 4-ethylester	DL
aspartate benzyl ester	L
6-diazo-5-oxo-norleucine	L

Tryptophan Family	
<i>Compound</i>	<i>Isomer</i>
tryptophan	L
6-fluorotryptophan	DL
5-fluorotryptophan	L
4-fluorotryptophan	DL
5-hydroxytryptophan	L

Phenylglycine Family	
<i>Compound</i>	<i>Isomer</i>
phenylglycine	L
4-hydroxyphenylglycine	L
4-fluorophenylglycine	L
4-methoxyphenylglycine	DL
amino-(4-nitro-phenyl)-acetic acid	DL
4-trifluoromethylphenylglycine	L
3-hydroxyphenylglycine	L
amino-(3-fluoro-phenyl)-acetic acid	DL
amino-(3-bromo-phenyl)-acetic acid	DL
3-trifluoromethylphenylglycine	DL
amino-(3-nitro-phenyl)-acetic acid	DL
2-fluorophenylglycine	DL

amino-o-tolyl-acetic acid	L
2-chlorophenylglycine	DL
3,4-difluorophenylglycine	DL
3-chloro-4-fluorophenylglycine	DL
3-fluoro-4-methylphenylglycine	DL
4-fluoro-3-methylphenylglycine	DL
3-carboxy-4-hydroxyphenylglycine	L
2-Cl, 5-OH phenylglycine	DL
3,4-dihydroxyphenylglycine	DL
3,5-dihydroxyphenylglycine	DL
4-carboxy-3-hydroxyphenylglycine	DL
2-phenylglycine methylester	L
(4-methoxyphenyl)(methylamino)acetic acid	DL
2-hydroxyphenylglycine	DL
amino-(2,3-dihydrobenzo [1,4]dioxin-6-yl) acetic acid	DL
amino-benzo[1,3]dioxol-5-yl acetic acid	DL
2-amino-2-[3-hydroxy-4-(hydroxymethyl)phenyl]acetic acid	DL
(4-fluorophenyl)-morpholin-4-yl-acetic acid	DL
cyclopropylalanine	L

Phenylalanine Family	
<i>Compound</i>	<i>Isomer</i>
homophenylalanine	L
2-amino-5-phenylpentanoic acid	L
4-hydroxyphenylalanine	L
3,4-dihydroxyphenylalanine	L
Quisqualic acid	L

Cysteine Family	
<i>Compound</i>	<i>Isomer</i>

cysteine	L
S-methyl-cysteine	L
S-ethyl-cysteine	L
S-phenyl-cysteine	L
S-benzyl-cysteine	L
S-(4-methylphenyl)-cysteine	L
penicillamine	L
homocysteine	L

Serine/Threonine Family	
<i>Compound</i>	<i>Isomer</i>
serine	L
serine	D
threonine	L
threonine	D
threonine	L-allo
threonine	DL-allo
O-methylserine	DL
O-acetylserine	L
benzylserine	L
beta (2-thienyl)serine	DL
3-pyridylserine	DL
serine methylester	L
serine-beta-naphthylamide	L
methionine	L
4-hydroxy-isoleucine	L
homoserine	D
homoserine	L

Cyclic Amino Acid Family	
<i>Compound</i>	<i>Isomer</i>

1-amino-1-carboxycyclopropane	
1-amino-1-carboxycyclobutane	
1-amino-1-carboxycyclopentane	
homocysteine thiolactone	L
homoserine lactone	L

Proline Family	
<i>Compound</i>	<i>Isomer</i>
proline	L
3,4-dehydroproline	L
4-hydroxy-L-proline	trans
4-fluoro-L-proline	trans
4-fluoro-L-proline	cis
γ-benzyl-L-proline	R
γ-(4-fluorobenzyl)-L-proline	R
1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid	S
2,3,4,9-tetrahydro-1H-beta-carboline-3-carboxylic acid	DL
2,3-dihydro-1H-isoindole-1-carboxylic acid	DL
4H-thieno[3,2-b]pyrrole-5-carboxylic acid	
azetidine-2-carboxylic acid	L
proline-beta naphthylamide	L
trans-4-cyclohexylproline	L
trans-4-hydroxyproline-naphthylamide	L
4,6-Dichloro-3-[(1E)-3-oxo-3-(phenylamino)-1-propenyl]-1H-indole-2-carboxylic acid	
(2S,3S,4S)-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid 4-methoxy-7-nitro-1H-indolinyI amide	
(E)-4,6-Dichloro-3-(2-phenyl-2-carboxyethenyl)indole-2-carboxylic acid	
γ-allyl-L-proline	R

aziridine-2-carboxylic acid	L
γ -(4-nitrobenzyl)-L-proline	R
trans-4-phenylproline	L
γ -(3,4-difluorobenzyl)-L-proline	R
γ -(3-thienylmethyl)-L-proline	R
γ -(4-methylbenzyl)-L-proline	R
γ -(2-naphthylenylmethyl)-L-proline	R
γ -propynyl-L-proline	R
γ -(3-fluorobenzyl)-L-proline	R
γ -(2-fluorobenzyl)-L-proline	R
γ -(4-bromobenzyl)-L-proline	R
γ -(4-chlorobenzyl)-L-proline HCl	R
γ -(4-iodobenzyl)-L-proline HCl	R
4H-thieno[3,2-b]pyrrole-5-carboxylic acid	
γ -(2-trifluoromethylbenzyl)-L-proline HCl	R
γ -(4-tertbutylbenzyl)-L-proline HCl	R
3-phenylproline	
γ -(2-cyanobenzyl)-L-proline HCl	R
γ -(2-methylbenzyl)-L-proline HCl	R
γ -(3-trifluoromethyl-benzyl)-L-proline HCl	R
γ -(3-phenyl-allyl)-L-proline HCl (Boc?)	R
γ -(1-naphthalenylmethyl)-L-proline HCl	R
4-(3-chlorobenzyl)pyrrolidine-2-carboxylic acid HCl	2S,4S
4-(3-chlorobenzyl)pyrrolidine-2-carboxylic acid HCl	2S,4R
4-benzyl-L-proline	S
γ -(2-furanylmethyl)-L-proline	S
γ -(3-chlorobenzyl)-L-proline HCl	R
γ -(2-pyridinylmethyl)-L-proline 2HCl	S
4-(3-chlorophenoxy)pyrrolidine-2-carboxylic acid HCl	2S,4R
4-(3-chlorophenoxy)pyrrolidine-2-carboxylic acid	2S,4S

HCl	
γ -(2-iodobenzyl)-L-proline HCl	R
γ -(3-benzothiienylmethyl)-L-proline HCl	R
γ -(2-bromobenzyl)-L-proline HCl	R
γ -(4-trifluoromethylbenzyl)-L-proline HCl	R
γ -(3-bromobenzyl)-L-proline HCl	R
γ -(4-pyridinylmethyl)-L-proline HCl	R
γ -(4-cyanobenzyl)-L-proline HCl	R
γ -(3-cyanobenzyl)-L-proline HCl	R
γ -(3,4-dichlorobenzyl)-L-proline HCl	R
γ -(2-chlorobenzyl)-L-proline HCl	R
γ -(2,4-dichlorobenzyl)-L-proline HCl	R
γ -propynyl-L-proline HCl	R
γ -(2-cyanobenzyl)-L-proline HCl	R
3-methyl-2-pyrrolidine-2-carboxylic acid	2S,3S
3-phenyl-2-pyrrolidine-2-carboxylic acid	2S,3R
(E)-4,6-Dichloro-3-(2-phenyl-2-carboxyethenyl)indole-2-carboxylic acid	
4,6-Dichloro-3-[(1E)-3-oxo-3-(phenylamino)-1-propenyl]-1H-indole-2-carboxylic acid	
Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid 4-methoxy-7-nitro-1H-indoliny l amide	(2S,3S,4S)

The compounds identified here in assays of D-serine transport are inhibitors of the transporter sub-types ASCT1 (SLC1A4) and ASCT2 (SLC1A5), as confirmed is transport assays using HEK cells that heterologously express human ASCT1 or

5 ASCT2. This includes the compounds L-gamma-glutamyl-4-nitroanilide, L-4-hydroxyphenylglycine, L-4-fluorophenylglycine, L-phenylglycine, trans-4-hydroxy-L-proline and R-gamma-2,4-dichlorobenzyl-L-proline. These compounds have IC₅₀ values less than 2mM in one or both assays of transport in HEK cells expressing ASCT1 or ASCT2.

To investigate the ability of compounds to improve visual function *in vivo*, compounds identified in the transport and *in vitro* LTP assays were selected for study in rodent models. These experiments show that L-4OHPG and L-4FPG enhance visual function in normal rats as assessed by sweep VEP (Figures 8 and 9), and that L-4OHPG enhances visually-evoked signals from the visual cortex in rats with optic nerve crush (Figure 10). L-4OHPG also enhanced sweep VEP in normal rabbits (Figure 11). In a model of macular degeneration, rats with damaged retinas following blue-light treatment were found to have a deficit in contrast sensitivity. Treatment with L-4OHPG showed a significant improvement in contrast sensitivity, restoring it towards normal levels (Figure 12). Thus, we have shown that compounds which inhibit D-serine transport can improve visual performance in normal rats and rabbits and in a two retinal disease models where visual performance has been impaired.

General Procedures Followed in Obtaining Experimental Data

Electrophysiological recording from rat hippocampal slices (Figures 1A-1B): 350 μ M thick hippocampal slices were prepared from 21- to 35-year-old rats using Leica VT1000S-microtome. Slices were perfused with ACSF containing: 121 mM NaCl, 2.5 mM KCl, 2.0 mM Mg_2SO_4 , 2.0 $CaCl_2$, 1 mM NaH_2PO_4 , 26.2 $NaHCO_3$, and 11 mM glucose, which was equilibrated with 5% CO_2 /95% O_2 . Experiments were performed in a recording chamber on the stage of an Olympus BX-61wi microscope with infrared DIC optics for visualizing whole-cell patch-clamp recordings. EPSPs were recorded from CA1 pyramidal neurons by stimulating the Schaffer collateral-commissural pathway using a bipolar tungsten electrode. The recording pipettes were filled with regular ICM containing: 120 mM Cs-gluconate, 5 mM NaCl, 10 mM KCl, 0.1 mM $CaCl_2$, 1 mM EGTA, 2 mM $MgCl_2$, 10 mM HEPES, 2 mM Na-ATP, 2 mM Na_2 -phosphocreatine, and 0.25 mM Na-GTP, pH 7.3 (290 mOsm).

To measure NMDA-mediated EPSCs, extracellular Mg_2SO_4 was lowered to 0.2 mM and 2 μ M NBQX and 100 μ M picrotoxin were added in the ACSF. 1 μ M 7-CKY (7-chlorokynurenic acid) was added to improve the sensitivity of EPSC_{NMDA} to D-serine.

Long Term Potentiation in Primary Visual Cortex (Figure 2)

Long Term Potentiation (LTP) in primary visual cortex has been used as a cellular model for visual cortex plasticity and has functional consequences on visual evoked responses. NMDA receptors play a critical role in visual cortex LTP induction.

5 *Visual Cortex Slice Physiology:* Following decapitation of the rat, the brain was rapidly removed and immersed in ice-cold artificial cerebrospinal fluid (ACSF) containing 124 mM NaCl, 3 mM KCl, 1.25 mM KH₂PO₄, 3.4 mM CaCl₂, 2.5 mM MgSO₄, 26 mM NaHCO₃, and 10 mM D-glucose. A block of visual cortex was created by removing the frontal 2/3 portion of the brain and the cerebellum. Coronal
10 visual cortex slices of 375 μ m were prepared from adult Sprague Dawley (SD) rats using a vibratome (VT 1000 S; Leica). The slices were maintained in an interface recording chamber perfused with preheated ACSF. Slices were continuously perfused with this solution at a rate of 1.00 -1.50 ml/min while the surface of the slices was exposed to warm, humidified 95% O₂/5% CO₂ and maintained at 31 $\pm$
15 1°C. Visual cortex slices were allowed to recover for 1hr before recording began. A single stimulating and recording electrode were placed in layer IV and III, respectively, to generate and record a field excitatory postsynaptic potentials (fEPSPs). Pulses were administered every 20 s using a current that produced a fEPSP that was 50 % of the maximum spike free response. An input-output (IO)
20 curve was done to determine the stimulation needed to achieve a stable baseline. Following a 15 min stable baseline recording period, a train of 5 theta bursts (each burst containing four pulses at 100 Hz with an inter-burst interval of 200ms) were delivered to the slice. This was repeated 2 additional times with a 1 minute intertrain interval, and the level of LTP was recorded for at least 30 min. Changes in amplitude
25 of the synaptic response were used to measure the extent of LTP because it was determined to be the more consistent parameter than the slope of the response. Control LTP values were obtained from slices not treated with drug. Different slices were used to study drug effects on LTP. After a 15 min baseline recording period, the compounds of interest were infused for 15 minutes followed by LTP induction.
30 Washout of the compounds began 5 minutes after tetanization. Recording of the amplitude before, during, and after drug infusion was done.

*DAAO Assay (Figures 2B):

For experiments with DAAO, 0.2 unit/ml of DAAO were infused with or without the compounds of interest for 15 minutes before LTP induction.

*Sweep VEP (Figures –8-12):

Data gathered through the sweep visually evoked potential assessment (sweep VEP, sVEP) show that L-4FPG and L-4OHPG enhance visual function in normal rats and rabbit and that L-4OHPG enhances remaining visual function in rats with optic nerve crush.

Sweep visually evoked potential (sweep VEP, sVEP), which was first introduced by Regan [1] in 1973, has become an important technique to measure visual function. It is an objective method that can be used to assess visual acuity (VA) and contrast sensitivity (CS) in infants, young children and people with special needs. It was adapted to measure VA and CS in animals.

VEP recording in rats: The recording electrodes were permanently implanted into the right visual cortex of Long Evans rats at lambda and 4.5 mm lateral to the midline, to a depth of 800 microns (layer III/IV). A reference electrode was placed epidurally on the midline 1.2 mm anterior to bregma. All recordings were conducted in awake rats starting at least two weeks after recovery from surgery. During recording the rats were alert and restrained in a home-made restrainer. They were habituated 2-3 times pre-surgery and at least three more times during seven days post-surgery. PowerDiva software from Anthony Norcia (Smith Kettlewell Institute of Visual Sciences) was used for data acquisition and analysis. Similar recording was performed in rabbits (Figure 11) except the screw electrodes were placed on top of the skull.

Visual stimuli for visual acuity measurement: Stimuli were presented on a CRT computer monitor and consist of full-field sine-wave gratings at 80% contrast, reversing at 6.25 Hz. VEPs were elicited by horizontally oriented gratings. The display was positioned 24 cm in front of the rat and centered at the vertical meridian. Mean luminance was held constant at 20 cd. For sVEP in normal rats (slides 76-79), one stimulus presentation (one trial) consists of a spatial frequency sweep decreasing from 1.6 to 0.03 cycles/degree in 15 linear steps. A total of 20 trials were collected. Visual acuity (VA) thresholds were estimated using PowerDiva software. For fixed frequency stimulus in optic nerve crushed (ONC) rats (slides 80-83), the

spatial frequency was fixed at 0.2 or 0.5 cycles/degree. Each trial lasts for 15 s. A total of 5 trials were collected and the signal powers were calculated.

Visual stimuli for Contrast sensitivity measurement: One stimulus presentation (one trial) consists of a contrast sweep increasing from 2.5 to 70 % in 15 log steps. A total of 20 to 30 trials were collected. Contrast thresholds (CT) were estimated using PowerDiva software. Contrast sensitivity (CS) is calculated as 1/CT.

Blue-light treatment damages photoreceptors in the retina, and has been proposed as a model of age related macular degeneration (ARMD; Wielgus et al., 2010). In blue-light treated Long-Evans rats, contrast sensitivity, an important measure of visual performance, was significantly impaired.

Transport experiments (See Tables herein and Figures 4-6)

Cell-based assays: the transport of [^3H]L- or D-serine was measured in primary cultures of rat hippocampal astrocytes or in human embryonic kidney (HEK) cells expressing ASCT transporter sub-types. For the astrocyte assays, cells were plated on either 24- or 96-well plates at a density of 50,000 cells per well. For the HEK assays, cells were plated on coated 96-well plates at a density of 80,000 cells/well. Assays were conducted in duplicate at room temperature in assay buffer consisting of: NaCl: 150mM, KCl: 2mM; MgCl₂: 1mM; CaCl₂: 1mM; HEPES: Tris buffer: 10mM, pH7.4. To assess the sodium-dependence of transport, NaCl was replaced in the assay buffer by equimolar choline chloride. Following aspiration of growth medium and 2 washes with assay buffer, cells were incubated with [^3H]L- or D-serine at a final concentration of 1 μM for 5 min (astrocytes) or 1 min (HEK cells), after which the incubation medium was aspirated and the cells washed twice with ice-cold assay buffer. Cells containing radiolabel were solubilized in 100 μl of 1% Triton-X100 and an aliquot counted in a beta counter. IC₅₀ values were determined over a range of at least 6 concentrations and derived from curve-fitting algorithms available in GraphPad Prism 4.

Synaptosome assays: a P2 fraction of rat forebrain was prepared and assayed immediately. Aliquots of the P2 preparation (approx. 1 mg of original tissue weight) were incubated in sodium-free assay buffer (CholineCl: 128mM, KCl: 3.5mM; KH₂PO₄: 1.5mM; MgCl₂: 1mM; CaCl₂: 1mM; glucose: 10mM; Tris-acetate buffer: 10mM, pH7.4) containing [^3H]D-serine (final concentration of 50 nM) and test

compounds in duplicate for 4 mins at room temperature. The synaptosomes containing radiolabel were collected by filtration onto Whatman GF/C filters, and washed twice with ice cold assay buffer. Filters were solubilized in scintillation fluid and radioactivity determined in a beta counter. IC₅₀ values were determined as described for the cell-based assays above.

5

We claim:

1. Use of an ophthalmically acceptable pharmaceutical composition comprising a pharmaceutically acceptable adjuvant, diluent or carrier and one or more D-serine transporter inhibitor compounds comprising L-gamma-glutamyl-4-nitroanilide, L-4-hydroxyphenylglycine, L-4-fluorophenylglycine, L-phenylglycine, trans-4-hydroxy-L-proline, R-gamma-2,4-dichlorobenzyl-L-proline, L-serine, D-serine, L-glutamine, L-asparagine, L-GPNA, L-glutamate- γ -benzyl ester, L-4-fluorophenylglycine, L-4-hydroxyphenylglycine, DL-2-fluorophenylglycine, L-phenylglycine, L-proline, S-benzyl-L-cysteine or S-phenyl-L-cysteine for the treatment of visual system disorders comprising macular edema, dry and wet macular degeneration, choroidal neovascularization, diabetic retinopathy, acute macular neuroretinopathy, central serous chorioretinopathy, cystoid macular edema, diabetic macular edema, uveitis, retinitis, choroiditis, acute multifocal placoid pigment epitheliopathy, Behcet's disease, birdshot retinochoroidopathy, syphilis, lyme, tuberculosis, toxoplasmosis, intermediate uveitis, multifocal choroiditis, multiple evanescent white dot syndrome, ocular sarcoidosis, posterior scleritis, serpiginous choroiditis, subretinal fibrosis and uveitis syndrome, Vogt-Koyanagi-and Harada syndrome; retinal arterial occlusive disease, anterior uveitis, retinal vein occlusion, central retinal vein occlusion, disseminated intravascular coagulopathy, branch retinal vein occlusion, hypertensive fundus changes, ocular ischemic syndrome, retinal arterial microaneurysms, Coat's disease, parafoveal telangiectasis, hemiretinal vein occlusion, papillophlebitis, central retinal artery occlusion, branch retinal artery occlusion, carotid artery disease, frosted branch angiitis, sickle cell retinopathy, angioid streaks, familial exudative vitreoretinopathy, Eales disease, sympathetic ophthalmia, uveitic retinal disease, retinal detachment, trauma, photocoagulation, hypoperfusion during surgery, radiation retinopathy, bone marrow transplant retinopathy, proliferative vitreal retinopathy and epiretinal membranes, proliferative diabetic retinopathy, ocular histoplasmosis, ocular toxocariasis, presumed ocular histoplasmosis syndrome, endophthalmitis, toxoplasmosis, retinal diseases associated with HIV infection, choroidal disease associate with HIV infection, uveitic disease associate with HIV infection, viral retinitis, acute retinal necrosis, progressive outer retinal necrosis,

fungal retinal diseases, ocular syphilis, ocular tuberculosis, diffuse unilateral subacute neuroretinitis, myiasis, retinitis pigmentosa, systemic disorders with associated retinal dystrophies, congenital stationary night blindness, cone dystrophies, Stargardt's disease and fundus flavimaculatus, Best's disease, pattern dystrophy of the retinal pigmented epithelium, X-linked retinoschisis, Sorsby's fundus dystrophy, benign concentric maculopathy, Bietti's crystalline dystrophy, pseudoxanthoma elasticum, retinal holes, retinal detachment, macular hole, giant retinal tear, retinal disease associated with tumors, congenital hypertrophy of the retinal pigmented epithelium, posterior uveal melanoma, choroidal hemangioma, choroidal osteoma, choroidal metastasis, combined hamartoma of the retina and retinal pigmented epithelium, retinoblastoma, vasoproliferative tumors of the ocular fundus, retinal astrocytoma, intraocular lymphoid tumors, punctate inner choroidopathy, acute posterior multifocal placoid pigment epitheliopathy, myopic retinal degeneration, acute retinal pigment epitheliitis, retinitis pigmentosa, proliferative vitreal retinopathy, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal detachment, retinal tear, uveitis, cytomegalovirus retinitis, glaucoma, amblyopia, stroke-induced blindness, visual dysfunction in Parkinson's disease, Alzheimer's disease and multiple sclerosis, seizure-induced cortical blindness, induced visual dysfunction, or epileptic blindness caused by a deficit in N-methyl -D-aspartate receptor function in a subject in need thereof.

2. The use according to claim 1, wherein the one or more D-serine transporter inhibitor compounds are L-gamma-glutamyl-4-nitroanilide, L-4-hydroxyphenylglycine, L-4-fluorophenylglycine, L-phenylglycine, trans-4-hydroxy-L-proline, R-gamma-2,4-dichlorobenzyl-L-proline, or a combination thereof.

3. The use according to claim 2, wherein the ophthalmically acceptable pharmaceutical composition comprises L-gamma-glutamyl-4-nitroanilide.

4. The use according to claim 2, wherein the ophthalmically acceptable pharmaceutical composition comprises L-4-hydroxyphenylglycine.

5. The use according to claim 2, wherein the ophthalmically acceptable pharmaceutical composition comprises L-4-fluorophenylglycine.

6. The use according to claim 2, wherein the ophthalmically acceptable pharmaceutical composition comprises L-phenylglycine.
7. The use according to claim 2, wherein the ophthalmically acceptable pharmaceutical composition comprises trans-4-hydroxy-L-proline.
8. The use according to claim 2, wherein the ophthalmically acceptable pharmaceutical composition comprises R-gamma-2,4-dichlorobenzyl-L-proline.
9. Use of an ophthalmically acceptable pharmaceutical composition comprising one or more D-serine transporter inhibitor compounds comprising L-gamma-glutamyl-4-nitroanilide, L-4-hydroxyphenylglycine, L-4-fluorophenylglycine, L-phenylglycine, trans-4-hydroxy-L-proline or R-gamma-2,4-dichlorobenzyl-L-proline and L-serine, D-serine, L-glutamine, L-asparagine, L-GPNA, L-glutamate-γ-benzyl ester, L-4-fluorophenylglycine, L-4-hydroxyphenylglycine, DL-2-fluorophenylglycine, L-phenylglycine, L-proline, S-benzyl-L-cysteine and S-phenyl-L-cysteine and a pharmaceutically acceptable adjuvant, diluent or carrier for the enhancement of visual function in a subject in need thereof.
10. The use according to claim 9, wherein the one or more D-serine transporter inhibitor compounds are L-gamma-glutamyl-4-nitroanilide, L-4-hydroxyphenylglycine, L-4-fluorophenylglycine, L-phenylglycine, or trans-4-hydroxy-L-proline, or a combination thereof.
11. The use according to claim 10, wherein the ophthalmically acceptable pharmaceutical composition comprises L-4-hydroxyphenylglycine.
12. The use according to claim 10, wherein the ophthalmically acceptable pharmaceutical composition comprises L-4-fluorophenylglycine.
13. The use according to claim 10, wherein the ophthalmically acceptable pharmaceutical composition comprises L-phenylglycine.
14. The use according to claim 10, wherein the ophthalmically acceptable pharmaceutical composition comprises L-gamma-glutamyl-4-nitroanilide.

15. The use according to claim 10, wherein the ophthalmically acceptable pharmaceutical composition comprises trans-4-hydroxy-L-proline.
16. The use according to claim 10, wherein the ophthalmically acceptable pharmaceutical composition comprises R-gamma-2,4-dichlorobenzyl-L-proline.
17. The use according to claim 1, wherein the D-serine inhibitor compound is: L-gamma-glutamyl-4-nitroanilide, L-4-hydroxyphenylglycine, L-4-fluorophenylglycine, L-phenylglycine, trans-4-hydroxy-L-proline, or R-gamma-2,4-dichlorobenzyl-L-proline.
18. An ophthalmically acceptable pharmaceutical composition comprising a pharmaceutically acceptable adjuvant, diluent or carrier and one or more D-serine transporter inhibitor compounds comprising L-gamma-glutamyl-4-nitroanilide, L-4-hydroxyphenylglycine, L-4-fluorophenylglycine, L-phenylglycine, trans-4-hydroxy-L-proline or R-gamma-2,4-dichlorobenzyl-L-proline and L-serine, D-serine, L-glutamine, L-asparagine, L-GPNA, L-glutamate- γ -benzyl ester, L-4-fluorophenylglycine, L-4-hydroxyphenylglycine, DL-2-fluorophenylglycine, L-phenylglycine, L-proline, S-benzyl-L-cysteine and S-phenyl-L-cysteine for the manufacture of a medicament for the treatment of visual system disorders comprising macular edema, dry and wet macular degeneration, choroidal neovascularization, diabetic retinopathy, acute macular neuroretinopathy, central serous chorioretinopathy, cystoid macular edema, diabetic macular edema, uveitis, retinitis, choroiditis, acute multifocal placoid pigment epitheliopathy, Behcet's disease, birdshot retinochoroidopathy, syphilis, lyme, tuberculosis, toxoplasmosis, intermediate uveitis, multifocal choroiditis, multiple evanescent white dot syndrome, ocular sarcoidosis, posterior scleritis, serpiginous choroiditis, subretinal fibrosis and uveitis syndrome, Vogt-Koyanagi-and Harada syndrome; retinal arterial occlusive disease, anterior uveitis, retinal vein occlusion, central retinal vein occlusion, disseminated intravascular coagulopathy, branch retinal vein occlusion, hypertensive fundus changes, ocular ischemic syndrome, retinal arterial microaneurysms, Coat's disease, parafoveal telangiectasis, hemiretinal vein occlusion, papillophlebitis, central retinal artery occlusion, branch retinal artery occlusion, carotid artery disease, frosted branch angiitis, sickle cell retinopathy, angioid streaks, familial exudative

vitreoretinopathy, Eales disease, sympathetic ophthalmia, uveitic retinal disease, retinal detachment, trauma, photocoagulation, hypoperfusion during surgery, radiation retinopathy, bone marrow transplant retinopathy, proliferative vitreal retinopathy and epiretinal membranes, proliferative diabetic retinopathy, ocular histoplasmosis, ocular toxocariasis, presumed ocular histoplasmosis syndrome, endophthalmitis, toxoplasmosis, retinal diseases associated with HIV infection, choroidal disease associate with HIV infection, uveitic disease associate with HIV infection, viral retinitis, acute retinal necrosis, progressive outer retinal necrosis, fungal retinal diseases, ocular syphilis, ocular tuberculosis, diffuse unilateral subacute neuroretinitis, myiasis, retinitis pigmentosa, systemic disorders with associated retinal dystrophies, congenital stationary night blindness, cone dystrophies, Stargardt's disease and fundus flavimaculatus, Best's disease, pattern dystrophy of the retinal pigmented epithelium, X-linked retinoschisis, Sorsby's fundus dystrophy, benign concentric maculopathy, Bietti's crystalline dystrophy, pseudoxanthoma elasticum, retinal holes, retinal detachment, macular hole, giant retinal tear, retinal disease associated with tumors, congenital hypertrophy of the retinal pigmented epithelium, posterior uveal melanoma, choroidal hemangioma, choroidal osteoma, choroidal metastasis, combined hamartoma of the retina and retinal pigmented epithelium, retinoblastoma, vasoproliferative tumors of the ocular fundus, retinal astrocytoma, intraocular lymphoid tumors, punctate inner choroidopathy, acute posterior multifocal placoid pigment epitheliopathy, myopic retinal degeneration, acute retinal pigment epitheliitis, retinitis pigmentosa, proliferative vitreal retinopathy, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal detachment, retinal tear, uveitis, cytomegalovirus retinitis, glaucoma, amblyopia, stroke-induced blindness, visual dysfunction in Parkinson's disease, Alzheimer's disease and multiple sclerosis, seizure-induced cortical blindness, induced visual dysfunction, or epileptic blindness caused by a deficit in N-methyl -D-aspartate receptor function in a subject in need thereof.

19. The composition according to claim 18, wherein the one or more D-serine transporter inhibitor compounds are L-gamma-glutamyl-4-nitroanilide, L-4-

hydroxyphenylglycine, L-4-fluorophenylglycine, L-phenylglycine, trans-4-hydroxy-L-proline, R-gamma-2,4-dichlorobenzyl-L-proline, or a combination thereof.

20. The composition according to claim 18, wherein the ophthalmically acceptable pharmaceutical composition comprises L-gamma-glutamyl-4-nitroanilide.

21. The composition according to claim 18, wherein the ophthalmically acceptable pharmaceutical composition comprises L-4-hydroxyphenylglycine.

22. The composition according to claim 18, wherein the ophthalmically acceptable pharmaceutical composition comprises L-4-fluorophenylglycine.

23. The composition according to claim 18, wherein the ophthalmically acceptable pharmaceutical composition comprises L-phenylglycine.

24. The composition according to claim 18, wherein the ophthalmically acceptable pharmaceutical composition comprises trans-4-hydroxy-L-proline.

25. The composition according to claim 18, wherein the ophthalmically acceptable pharmaceutical composition comprises R-gamma-2,4-dichlorobenzyl-L-proline.

26. An ophthalmically acceptable pharmaceutical composition comprising a pharmaceutically acceptable adjuvant, diluent or carrier and one or more D-serine transporter inhibitor compounds comprising L-gamma-glutamyl-4-nitroanilide, L-4-hydroxyphenylglycine, L-4-fluorophenylglycine, L-phenylglycine, trans-4-hydroxy-L-proline or R-gamma-2,4-dichlorobenzyl-L-proline and L-serine, D-serine, L-glutamine, L-asparagine, L-GPNA, L-glutamate- γ -benzyl ester, L-4-fluorophenylglycine, L-4-hydroxyphenylglycine, DL-2-fluorophenylglycine, L-phenylglycine, L-proline, S-benzyl-L-cysteine and S-phenyl-L-cysteine for the manufacture of a medicament for the enhancement of visual function in a subject in need thereof.

27. The composition according to claim 26, wherein the one or more D-serine transporter inhibitor compounds are L-gamma-glutamyl-4-nitroanilide, L-4-hydroxyphenylglycine, L-4-fluorophenylglycine, L-phenylglycine, or trans-4-hydroxy-L-proline, or a combination thereof.

28. The composition according to claim 27, wherein the ophthalmically acceptable pharmaceutical composition comprises L-4-hydroxyphenylglycine.
29. The composition according to claim 27, wherein the ophthalmically acceptable pharmaceutical composition comprises L-4-fluorophenylglycine.
30. The composition according to claim 27, wherein the ophthalmically acceptable pharmaceutical composition comprises L-phenylglycine.
31. The composition according to claim 27, wherein the ophthalmically acceptable pharmaceutical composition comprises L-gamma-glutamyl-4-nitroanilide.
32. The composition according to claim 27, wherein the ophthalmically acceptable pharmaceutical composition comprises trans-4-hydroxy-L-proline.
33. The composition according to claim 27, wherein the ophthalmically acceptable pharmaceutical composition comprises R-gamma-2,4-dichlorobenzyl-L-proline.

Figure 1A




Figure 1B




Figure 2A




Figure 2B




Figure 3A




Figure 3B




Figure 4




Figure 5




Figure 6A




Figure 6B





Figure 7




Figure 8




Figure 9




Figure 10




Figure 11






Figure 12



A**B**